# REMED BrainStim

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/remed-brainstim

- Industry: Medical Devices & Equipment
- Headquarters: Seongnam-si, South Korea
- Website: www.nextqure.com
- Total disclosed funding: $2.6M
- Latest round: Seed (May 26, 2023)
- Investors on record: 2

## About

Founded in 2020 and based in Gyeonggi-do, South Korea, REMED BrainStim operates as a neurological health company that offers transcranial magnetic stimulation devices. In May 2023, REMED BrainStim raised KRW 3.5 billion in seed funding from COMES Investment and SL Investment. The company specializes in transcranial magnetic stimulation (TMS), a noninvasive treatment that involves using a magnetic coil to modify the natural electrical activity of the patient's brain. The company offers a variety of products, such as Mensa: Mon is a learning aid device that uses electromagnetic stimulation to help users improve their concentration and memory; emQure activates the frontal and temporal lobes associated with memory formation to improve language memory and cognitive function; emFree is a miniaturized version of TMS for depression treatment that has the most clinical data among various TMS treatments; and hair breath is a product that overcomes the limitations of existing laser treatments. NextQure also provides a network platform for managing patients' continuous therapy. The organization intends to utilize the funds from May 2023 to promote household acceptance of its transcranial magnetic stimulation devices as well as to create new products for the treatment of intractable diseases, emotional therapy, addiction treatment, and sleep therapy.

## Funding rounds

- Seed, May 26, 2023, $2.6M — SL Investment, COMES Investment

## Investors

- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Seed
- COMES Investment (https://capitalatlas.ai/funds/comes-investment) — Seed